Cargando…

Elucidations on the Performance and Reversibility of Treatment with Hyaluronic Acid Based Dermal Fillers: In vivo and in vitro Approaches

PURPOSE: The aim of this study was to investigate the performance and the reversibility of different classes of Hyaluronic Acid (HA) dermal fillers. We analysed 4 HA based fillers, belonging to 3 different chemical classes of products, commonly used in the field of wrinkles correction: linear HA 8 m...

Descripción completa

Detalles Bibliográficos
Autores principales: Scrima, Mario, Merola, Filomena, Vito, Nicoletta, Pacchioni, Daniele, Vecchi, Gabriele, Melito, Carmela, Iorio, Antonio, Giori, Andrea Maria, Ferravante, Angela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9744867/
https://www.ncbi.nlm.nih.gov/pubmed/36523543
http://dx.doi.org/10.2147/CCID.S383354
_version_ 1784849020867313664
author Scrima, Mario
Merola, Filomena
Vito, Nicoletta
Pacchioni, Daniele
Vecchi, Gabriele
Melito, Carmela
Iorio, Antonio
Giori, Andrea Maria
Ferravante, Angela
author_facet Scrima, Mario
Merola, Filomena
Vito, Nicoletta
Pacchioni, Daniele
Vecchi, Gabriele
Melito, Carmela
Iorio, Antonio
Giori, Andrea Maria
Ferravante, Angela
author_sort Scrima, Mario
collection PubMed
description PURPOSE: The aim of this study was to investigate the performance and the reversibility of different classes of Hyaluronic Acid (HA) dermal fillers. We analysed 4 HA based fillers, belonging to 3 different chemical classes of products, commonly used in the field of wrinkles correction: linear HA 8 mg/mL (Viscoderm 0.8), thermically stabilized hybrid complexes of high and low molecular weight HA molecules at a concentration of 32 mg/mL and 45 mg/mL respectively (Profhilo and Profhilo Structura) and cross-linked HA 25 mg/mL (Aliaxin GP). METHODS: The products were tested by a well-established animal model. The generated implants were analyzed through High-Frequency Ultrasound technology. Then, reversibility of the treatment was evaluated by enzymatic degradation kinetics studies, characterised by a combined approach of Carbazole assay and HP-SEC/TDA method. RESULTS: Implants generated by linear HA 8 mg/mL remained detectable by ultrasound acquisition for 4 weeks, whereas those generated by injection of HA hybrid complex 32 mg/mL were detectable for 10 weeks. HA hybrid complex 45 mg/mL and cross-linked HA 25 mg/mL were detectable for 29 and at least 33 weeks, respectively. Enzymatic degradation kinetics studies demonstrated that the HA content in HA hybrid complex 45 mg/mL was almost completely depolymerized and homogeneous after 3 h of treatment. For cross-linked HA 25 mg/mL, 24 h of incubation are needed to obtain the same degree of depolymerization. CONCLUSION: The study confirmed the ability of the experimental model to predict the behaviour of HA based dermal fillers in vivo and showed the innovative aspects of HA hybrid complex 45 mg/mL, that combines the high-safety profile, in terms of reversibility of the treatment, of the linear HA-based products with the durability of a high degree cross-linked gels, paving the way to the chance to be used for a wide range of applications in the field of aesthetic medicine.
format Online
Article
Text
id pubmed-9744867
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-97448672022-12-14 Elucidations on the Performance and Reversibility of Treatment with Hyaluronic Acid Based Dermal Fillers: In vivo and in vitro Approaches Scrima, Mario Merola, Filomena Vito, Nicoletta Pacchioni, Daniele Vecchi, Gabriele Melito, Carmela Iorio, Antonio Giori, Andrea Maria Ferravante, Angela Clin Cosmet Investig Dermatol Original Research PURPOSE: The aim of this study was to investigate the performance and the reversibility of different classes of Hyaluronic Acid (HA) dermal fillers. We analysed 4 HA based fillers, belonging to 3 different chemical classes of products, commonly used in the field of wrinkles correction: linear HA 8 mg/mL (Viscoderm 0.8), thermically stabilized hybrid complexes of high and low molecular weight HA molecules at a concentration of 32 mg/mL and 45 mg/mL respectively (Profhilo and Profhilo Structura) and cross-linked HA 25 mg/mL (Aliaxin GP). METHODS: The products were tested by a well-established animal model. The generated implants were analyzed through High-Frequency Ultrasound technology. Then, reversibility of the treatment was evaluated by enzymatic degradation kinetics studies, characterised by a combined approach of Carbazole assay and HP-SEC/TDA method. RESULTS: Implants generated by linear HA 8 mg/mL remained detectable by ultrasound acquisition for 4 weeks, whereas those generated by injection of HA hybrid complex 32 mg/mL were detectable for 10 weeks. HA hybrid complex 45 mg/mL and cross-linked HA 25 mg/mL were detectable for 29 and at least 33 weeks, respectively. Enzymatic degradation kinetics studies demonstrated that the HA content in HA hybrid complex 45 mg/mL was almost completely depolymerized and homogeneous after 3 h of treatment. For cross-linked HA 25 mg/mL, 24 h of incubation are needed to obtain the same degree of depolymerization. CONCLUSION: The study confirmed the ability of the experimental model to predict the behaviour of HA based dermal fillers in vivo and showed the innovative aspects of HA hybrid complex 45 mg/mL, that combines the high-safety profile, in terms of reversibility of the treatment, of the linear HA-based products with the durability of a high degree cross-linked gels, paving the way to the chance to be used for a wide range of applications in the field of aesthetic medicine. Dove 2022-12-08 /pmc/articles/PMC9744867/ /pubmed/36523543 http://dx.doi.org/10.2147/CCID.S383354 Text en © 2022 Scrima et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Scrima, Mario
Merola, Filomena
Vito, Nicoletta
Pacchioni, Daniele
Vecchi, Gabriele
Melito, Carmela
Iorio, Antonio
Giori, Andrea Maria
Ferravante, Angela
Elucidations on the Performance and Reversibility of Treatment with Hyaluronic Acid Based Dermal Fillers: In vivo and in vitro Approaches
title Elucidations on the Performance and Reversibility of Treatment with Hyaluronic Acid Based Dermal Fillers: In vivo and in vitro Approaches
title_full Elucidations on the Performance and Reversibility of Treatment with Hyaluronic Acid Based Dermal Fillers: In vivo and in vitro Approaches
title_fullStr Elucidations on the Performance and Reversibility of Treatment with Hyaluronic Acid Based Dermal Fillers: In vivo and in vitro Approaches
title_full_unstemmed Elucidations on the Performance and Reversibility of Treatment with Hyaluronic Acid Based Dermal Fillers: In vivo and in vitro Approaches
title_short Elucidations on the Performance and Reversibility of Treatment with Hyaluronic Acid Based Dermal Fillers: In vivo and in vitro Approaches
title_sort elucidations on the performance and reversibility of treatment with hyaluronic acid based dermal fillers: in vivo and in vitro approaches
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9744867/
https://www.ncbi.nlm.nih.gov/pubmed/36523543
http://dx.doi.org/10.2147/CCID.S383354
work_keys_str_mv AT scrimamario elucidationsontheperformanceandreversibilityoftreatmentwithhyaluronicacidbaseddermalfillersinvivoandinvitroapproaches
AT merolafilomena elucidationsontheperformanceandreversibilityoftreatmentwithhyaluronicacidbaseddermalfillersinvivoandinvitroapproaches
AT vitonicoletta elucidationsontheperformanceandreversibilityoftreatmentwithhyaluronicacidbaseddermalfillersinvivoandinvitroapproaches
AT pacchionidaniele elucidationsontheperformanceandreversibilityoftreatmentwithhyaluronicacidbaseddermalfillersinvivoandinvitroapproaches
AT vecchigabriele elucidationsontheperformanceandreversibilityoftreatmentwithhyaluronicacidbaseddermalfillersinvivoandinvitroapproaches
AT melitocarmela elucidationsontheperformanceandreversibilityoftreatmentwithhyaluronicacidbaseddermalfillersinvivoandinvitroapproaches
AT iorioantonio elucidationsontheperformanceandreversibilityoftreatmentwithhyaluronicacidbaseddermalfillersinvivoandinvitroapproaches
AT gioriandreamaria elucidationsontheperformanceandreversibilityoftreatmentwithhyaluronicacidbaseddermalfillersinvivoandinvitroapproaches
AT ferravanteangela elucidationsontheperformanceandreversibilityoftreatmentwithhyaluronicacidbaseddermalfillersinvivoandinvitroapproaches